Drug Interaction Study

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

May 14, 2024

Study Completion Date

May 22, 2024

Conditions
Drug Interaction
Interventions
DRUG

Itraconazole

itraconazole 200 mg QD Days 6 to 16

DRUG

rifampicin

rifampicin 600 mg QD Days 6 to 20

DRUG

Ecopipam

89.6 mg on Days 1 and 9 for Part 1 or 179.2 mg on Days 1 and 13 for Part 2

Trial Locations (1)

G1P 0A2

Syneos Health Clinic Inc., Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

Cambridge Cognition Ltd

INDUSTRY

lead

Emalex Biosciences Inc.

INDUSTRY

NCT06194864 - Drug Interaction Study | Biotech Hunter | Biotech Hunter